New immunisation reference page: Pneumococcal disease and vaccines

Invasive pneumococcal disease (IPD) can manifest in many different ways causing disease of varied severity. Certain individuals with specific medical conditions are considered at an increased risk of IPD and therefore are recommended to receive additional vaccines. Our new reference page discusses the different pneumococcal vaccines available and outlines the different immunisation recommendations for each patient group.

To read more follow the link below:

MVEC: Pneumococcal disease and vaccines

Registrations now open for the March CVU miniseries event

The next Clinical Vaccinology Update (CVU) miniseries event, COVID-19 vaccines: engagement, communication and safety, will be held virtually on Tuesday 9th March, 2021.

We are excited to welcome our panel who will be presenting on COVID-19 vaccine stakeholder engagement, participation and communication, as well as giving an update on the Victorian Specialist Immunisation Service (VicSIS) and international vaccine safety.

A full program of this free event can be found via our Events page and the link below:

CVU mini: March 9th, 2021

A recording of the February CVU mini is now available

Thank you to all who attended our recent CVU miniseries event COVID-19 Vaccines: A Victorian Landscape on February 8th 2021.

Presentation topics included COVID-19 vaccine platforms, COVID-19 vaccine safety, COVID-19 vaccine rollout in Victoria, as well as stakeholder engagement and participation.

A free recording of this event is now available via our education portal.

To access this recording please follow the link below:

CVU mini- 8th February 2021

Victorian COVID-19 e-Learning Competency

Developed in partnership with the Victorian Government Department of Health, The Victorian COVID-19 e-Learning Competency is the latest course available on the MVEC education portal. This competency forms part of the pre-requisite training requirements for Victorian emergency authorised registered health professionals to administer COVID -19 vaccines.

The aim of completing this competency is to assist health professionals to be appropriately trained and competent to deliver COVID-19 vaccines.

To access this competency please follow the link below:

MVEC Education Portal: Victorian COVID-19 eLearning Competency

TGA provisionally approves AstraZeneca's COVID-19 vaccine

Following a thorough review process, informed by expert and independent advice from the Advisory Committee on Vaccines (ACV), the TGA has granted provisional approval for the University of Oxford/AstraZeneca COVID-19 vaccine.

Provisional registration will allow COVID-19 Vaccine AstraZeneca to be administered to individuals 18 years and over for the prevention of COVID-19 disease caused by SARS-CoV-2. The 2 dose course may be administered with a 4-12 week interval, with ATAGI preferring doses separated by 12 weeks. In certain circumstances an interval of 4 weeks is acceptable.

Of note, there were no safety concerns revealed in clinical trials involving patients >65 years of age and a strong immune response was demonstrated. However due to insufficient numbers of participants infected with SARS-CoV-2 in this age group, efficacy could not be conclusively determined. As a result, the immunisation of individuals in this age group should be decided on a case-by-case basis.

Supply of this vaccine will initially be imported from overseas, with ongoing supply of vaccines to be manufactured in Australia.

To read the press release in full follow the link below:

TGA provisionally approves AstraZeneca's COVID-19 vaccine

Building a stronger Australian Immunisation Register

A change in legislation, making it a requirement for all vaccination providers to report every vaccine to the Australian Immunisation Register (AIR), has passed through Parliament.

This will allow for a more comprehensive reporting of immunisation data to help enhance vaccination coverage rates and monitor the effectiveness of Australia's immunisation program.

Every COVID-19 vaccine administered within Australia must reported to AIR. From March 1, 2021 every Influenza vaccine must be included and all other NIP vaccines must be reported from July 1, 2021.

To understand more about the new legislation please refer to the press release below:

Building a stronger Australian Immunisation Register


BBC- Covid: New Oxford vaccine 'ready by the autumn' to tackle mutations

With the emergence of various mutations of SARS-CoV-2 there is still reassuring evidence that existing vaccines are providing good protection, although at a slightly less rate than with the initial variants. Additionally, interim results released by the Oxford/AstraZeneca team showed that vaccination with the Oxford/AstraZeneca COVID-19 vaccine could cut transmission of the virus by up to 67%.

In the following article published in the BBC, Professor Andy Pollard from Oxford University suggests that updating vaccines to make them more effective against mutations is a quick process. With manufacturing processes already established, newer vaccines could be available relatively quickly.

To read more follow the link below:

BBC- Covid: New Oxford vaccine 'ready by the autumn' to tackle mutations


New immunisation reference page: Drive-through immunisation clinics

Drive-through immunisation clinics are an alternative venue for supporting vaccine delivery and can assist members of the community to continue to receive recommended immunisations whilst maintaining physical distancing.

Our new reference page highlights the equipment, staffing and logistics to consider when setting up a drive-through clinic.

To access this resource please visit our Immunisation References or follow the link below:

MVEC: Drive-through immunisation clinics

Latest monitoring data confirms safety of COVID-19 vaccines

Data from the UK's independent medicines regulator (MHRA) has confirmed that the safety profile of the approved COVID-19 vaccines (Oxford Astra/Zeneca and Pfizer/BioNTech) remains as high as reported in the clinical trial data that supported those approvals.

With over 10 million doses already delivered, there have been 22,820 reports of suspected side effects with the majority being short-lasting, mild and expected side effects including sore arms and 'flu-like' symptoms.

To read the press release in full follow the link below:

Latest monitoring data confirms safety of COVID-19 vaccines


CVU Miniseries event February 8, 2021- registration closing soon

COVID-19 vaccines: A Victorian landscape is the first event in our CVU Miniseries for 2021.

Please join us online on Monday the 8th of February at 7pm to hear about COVID-19 vaccine safety and Victorian COVID-19 vaccine rollout information.

To view the full program and to register, please visit our Event page.

Registrations for this FREE event will close on Monday the 8th of February at 2pm.

A recording of COVID-19 vaccines: A Victorian landscape will be accessible on our Education Portal following the event.